COR bets on MSOs, specialty logistics and AI tools to deepen ties beyond distribution???even as GLP-1 mix and pricing swings cloud results.
Cencora (COR) reported earnings 30 days ago. What's next for the stock?
The mean of analysts' price targets for Cencora (COR) points to a 33.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
| Consumer Staples Distribution & Retail Industry | Consumer Staples Sector | Robert Mauch CEO | XWBO Exchange | US03073E1055 ISIN |
| US Country | 47,000 Employees | 1 Jun 2026 Last Dividend | 16 Jun 2009 Last Split | 4 Apr 1995 IPO Date |
Cencora, Inc., previously known as AmerisourceBergen Corporation, is a global leader in healthcare solutions, with a focus on improving patient outcomes through the efficient distribution and commercialization of pharmaceuticals and healthcare-related products. Established in 2001 and headquartered in Conshohocken, Pennsylvania, Cencora has expanded its reach by providing a wide range of services to various healthcare providers, including acute care hospitals, retail pharmacies, mail order pharmacies, and specialists across numerous disease states. The company's commitment to offering comprehensive supply chain management services, specialized software, and consulting services underscores its integral role in the healthcare sector. Through its U.S. Healthcare Solutions and International Healthcare Solutions segments, Cencora, Inc. addresses the nuanced needs of its global client base, delivering tailored services that encompass distribution, commercialization, logistics, and much more.